An ANDA number beats a nameless blister every time

ANDA 80-125% is a test, not a mail blister

The 80-125% window is a statistics test. It is not a shipping method. An ANDA sponsor shows that AUC and Cmax 90% confidence intervals sit inside that band versus the reference listed drug. That result is a card in the PMX stack. A blister that arrived with no application number is not the same object.

People collapse those two things because both tablets can look blue. The test does not travel with the pack. If there is no ANDA, there is no 80-125% figure to cite. Calling the pack generic is a habit, not an Orange Book rating.

This library files three PDE5 cards - sildenafil, tadalafil, vardenafil. Each ceiling on those cards assumes a licensed tablet. Informal film packs do not inherit the ceiling language. If the powder is real, nitrates still drop blood pressure. You just have no file when someone asks which ANDA you took.

Read the NDC before you call it generic

PMX stack sort, August 2026: three channels, one NDC rule. Licensed counter and licensed mail stay on the card. Informal packs do not. Not a cart.

Read the NDC before you call it generic. The digits map to a labeler and a strength. A licensed US pharmacy prints them. A licensed mail pharmacy prints them. An unlicensed pack often prints a story instead.

AB in the Orange Book is a substitution code for one strength of one molecule. It is not a compliment you give a website. If you cannot name the ANDA holder, you are not holding a generic card. You are holding a guess. The table below is a stack sort, not a price list.

Introduction: Why Generic PDE5 Questions Keep Showing Up in Clinic

Nitrates plus any AB-rated PDE5 tablet can kill - generic status changes the copay, not the contraindication.

Men ask a predictable question at every generic switch: "Is this the same as Viagra?" Split the answer: regulatory yes for population PK under fasting BE studies; clinical maybe for tonight after a heavy dinner and a new pill color.

That economic shift is real and clinically meaningful. Claims analyses link lower copays to better refill persistence for chronic conditions; for as-needed ED therapy, cost determines whether a man fills a second script or quietly stops treatment. Generic entry expanded access without changing the underlying pharmacology: every approved tablet still blocks PDE5, still requires sexual stimulation for useful effect, and still kills you with nitrates if you ignore the contraindication.

Confusion enters when patients conflate three distinct questions: (1) Is this tablet the same drug substance and strength as the brand I used before? (2) Did the FDA accept a bioequivalence study showing comparable absorption under standardized conditions? (3) Will I subjectively experience identical timing and rigidity tonight? The first two are regulatory questions with documentable answers. The third introduces meal timing, gastric emptying, CYP3A4 phenotype, adherence, and nocebo when the pill color changes.

Your job in clinic and at the pharmacy counter is to separate regulatory equivalence from therapeutic experimentation across molecules. Switching from generic sildenafil made by Manufacturer A to Manufacturer B is not the same decision as switching from sildenafil to tadalafil because a podcast said daily dosing is superior. The former is substitution within one ANDA pathway; the latter is a new prescription with different half-life, food interactions, and dose strengths.

Card note: sildenafil, tadalafil, and vardenafil-the three PDE5 inhibitors with full monographs on this site. It does not treat compounded sublingual products, unapproved analogues sold online, or cross-border tablets that never passed a U.S. ANDA review as interchangeable with anything.

Primary care sees most refill requests. Urology still handles refractory cases and post-procedural rehabilitation. Pharmacy receives the substitution call when the wholesaler changes ANDA supplier. Each setting needs the same core message: AB-rated means PK-equivalent under FDA test conditions, not a promise that tonight feels identical to the first Cialis trial fifteen years ago.

Document what you told the patient about meals, timing, and nitrates when they return saying the new pill failed. Many failures are fixable without abandoning generics-adjust timing, confirm strength, rule out new isosorbide from cardiology, retry a different AB manufacturer before rewriting the molecule entirely.

Warehouse club pharmacies and mail-order benefit designs rotate suppliers by contract quarter. Patients on stable regimens may see new NDC numbers without clinical consultation-that is expected substitution, not an error requiring urgent urology visit unless adverse effects appear.

Step therapy policies that require generic sildenafil before brand tadalafil daily reflect payer economics. Clinicians document adequate sildenafil trials with correct fasting timing before appeals; pharmacologic non-inferiority across molecules is not the legal basis for appeal-documented inadequate response is.

Generic market share for sildenafil exceeds ninety percent in many U.S. payers today; younger men may never have seen innovator packaging. Their questions about equivalence are still valid-answer with BE framework language, not dismissive reassurance.

Regulatory Framework: ANDA Requirements and the 80-125% Confidence Interval

Generic approval rests on two pillars: pharmaceutical equivalence and bioequivalence to the reference listed drug (RLD). For oral PDE5 tablets, that means the same active ingredient, dosage form, route, and strength, plus PK similarity in a crossover study powered on AUC and C_max.

Card note: an abbreviated new drug application (ANDA) is not a repeat of the innovator's Phase III erectile function trials. The applicant demonstrates that their product delivers the same active moiety to systemic circulation at a comparable rate and extent under the test conditions FDA specifies for that RLD. Clinical efficacy in ED is inferred from the innovator's registration data plus PK bridging-not re-proven de novo in thousands of men for each new tablet binder.

Standard bioequivalence analysis logs AUC_0-t (and usually AUC_0-inf) and C_max, then constructs 90% confidence intervals for the ratio of generic to reference geometric means. Those intervals must fall entirely within 80% to 125% for approval. The interval is 90%, not 95%, because regulators treat bioequivalence as a two one-sided test problem at the 5% alpha level each side.

That window looks wide until you remember it applies to log-transformed ratios in healthy volunteers, typically 24-36 subjects in a two-period crossover with adequate washout. A generic that barely passes might sit near the lower bound for C_max and the upper bound for AUC; another manufacturer of the same molecule might cluster tightly around 100%. Both are legally equivalent; individual patients can land on different tails of absorption variability.

Pharmaceutical equivalence also demands sameness of active ingredient, strength, and dosage form. Salt form matters: sildenafil citrate and tadalafil in approved tablets must match the RLD's form. Excipients differ by design-colorants, lactose, croscarmellose-and can change GI tolerability without failing PK endpoints averaged across the study cohort.

Product-specific guidances (PSGs) published by FDA spell out recommended study designs per strength. PDE5 inhibitors are not biopharmaceutics classification system (BCS) class I compounds with simple dissolution waivers; in vivo BE studies remain the norm. Post-approval changes-scale-up, new manufacturing site, alternate excipient supplier-require comparability protocols and may trigger additional dissolution or BE work if the change is deemed significant.

What ANDA science does not prove: superiority to other PDE5 molecules, erectile function outcomes in diabetic neuropathy, or performance when the patient splits an unscored tablet to save money. It also does not compare one generic company to another-only each applicant versus its chosen RLD at approval time.

Reference-scaled average bioequivalence (RSABE) may apply to highly variable drugs when within-subject variability for C_max or AUC exceeds FDA thresholds. Sildenafil shows moderate variability; sponsors still design adequately powered studies. Understanding RSABE explains occasional wider acceptance limits in specific high-variance molecules-check the actual PSG for each strength rather than assuming one rule fits all PDE5 products.

Multiple-dose steady-state studies appear for daily tadalafil strengths where accumulation matters. PRN sildenafil relies on single-dose crossover designs because steady state is not achieved with as-needed use. Mixing up those paradigms when reading ANDA review documents leads to wrong conclusions about what was demonstrated.

Citizen petitions and competitive ANDA litigation occasionally delay approvals but rarely change BE criteria once products reach market. The science gate remains AUC and C_max ratios in labeled study conditions.

Card note: clinical pharmacology reviews in FDA approval packages publish geometric mean ratios and confidence intervals for each strength-primary documents when teaching regulatory science. Published BE papers in peer-reviewed journals mirror those datasets with volunteer demographics that exclude hepatic disease, concomitant CYP inhibitors, and elderly frailty common in real prescribers' panels.

Waivers for in vivo BE in lower strengths require established dose proportionality from higher strength data plus matching dissolution profiles. Tadalafil 2.5 mg daily may use 5 mg data under specific protocols; prescribers still treat each strength as a distinct prescription.

Volunteer BE studies exclude women; extrapolation to female partners is irrelevant for ED indication but reminds clinicians that PK tables describe young healthy male volunteers, not your seventy-year-old patient on diltiazem and metformin.

Orange Book AB Ratings and Pharmacy Substitution

FDA's Approved Drug Products with Therapeutic Equivalence Evaluations-the Orange Book-lists approved products with therapeutic equivalence (TE) codes. For oral solid PDE5 generics that meet standard BE criteria, the code is almost always AB.

The AB rating means FDA has evaluated bioequivalence and pharmaceutical equivalence data and considers the generic substitutable for the reference product at the pharmacy level in states that allow generic substitution unless the prescriber marks dispense as written. A BX rating-rare for mainstream PDE5 tablets-signals unresolved equivalence questions; pharmacies should not auto-substitute BX-coded products.

Each Orange Book entry ties a product to an application number, RLD linkage, and strength. Multiple ANDA holders for sildenafil 100 mg tablets may all carry AB ratings against Viagra, but they are different products with different NDC numbers, packaging, and excipient lists. When a patient says the pharmacy "changed my generic," they usually mean a different ANDA holder while the TE code stayed AB.

Therapeutic equivalence codes apply molecule-by-molecule and strength-by-strength. AB-rated generic tadalafil 5 mg daily is substitutable for Cialis 5 mg daily; it is not substitutable for tadalafil 20 mg PRN or for sildenafil 100 mg. Pharmacy software maps TE codes to state law; your prescription must specify the correct strength and molecule when you intend a particular regimen.

Card note: prescribers sometimes write brand names out of habit while intending generic dispensing. Pharmacists substitute AB products unless DAW codes apply. If a patient insists the brand works better after years on a stable generic, the pharmacologic argument for medical necessity is weak unless documented excipient allergy or intolerance-yet insurance may require prior authorization for brand when AB generics exist.

International travelers sometimes carry tablets purchased abroad. EMA-approved generics meet European BE rules; they are not automatically listed in the U.S. Orange Book. Strength labeling differs (tadalafil 20 mg EU versus U.S. labeling conventions); salt forms and counterfeit risk complicate casual importation. Licensed U.S. AB products remain the reference for counseling in American practice.

When teaching residents, map the AB code to what it guarantees (PK under BE study conditions) and what it does not (identical patient-reported onset, interchange across molecules, or quality assurance for products bought without a prescription).

State laws differ on mandatory substitution and patient refusal rights. Some states allow pharmacists to substitute AB products unless DAW; others require patient consent. Prescriber frustration with substitution often reflects unawareness of those statutes rather than pharmacologic inferiority.

Revatio-branded sildenafil for pulmonary arterial hypertension and Viagra for ED share active moiety but differ in strength, dosing frequency, and indication. Orange Book entries are strength-specific; dispensing 20 mg TID Revatio logic against a 100 mg Viagra-equivalent generic is a medication error unrelated to BE status.

Medicaid and Medicare formularies prefer lowest-cost AB generic within molecule. Prior authorization for brand when AB exists requires documented intolerance-not preference shaped by advertising.

Look-alike packaging between strengths within one manufacturer's line causes dispensing errors-100 mg dispensed instead of 25 mg is a patient safety event unrelated to bioequivalence science. Barcode scanning and patient teach-back on strength digits prevent confusion after generic switch.

Fasting Versus Fed Bioequivalence Studies

BE studies run under fasting or fed conditions depending on product-specific guidance and the RLD label's food-effect language. Matching the reference condition matters more than which condition feels convenient in real life.

Sildenafil's reference label documents clinically meaningful food effects: high-fat meals delay T_max by roughly an hour and reduce C_max and AUC modestly. FDA PSGs for sildenafil generics therefore specify fasting BE studies so generics match Viagra under the same empty-stomach paradigm used for approval. Counseling about avoiding heavy meals before sex applies equally to every AB-rated sildenafil tablet-not because the generic is inferior, but because the molecule's absorption is food-sensitive.

Vardenafil shows similar high-fat meal delays in labeling; BE studies typically fast subjects. Patient instructions about timing relative to dinner remain relevant after generic switch.

Card note: tadalafil is the outlier in this class. The reference product's label describes minimal influence of food on absorption for ED doses. Generics are still studied under fasting conditions in most ANDA programs, but real-world timing flexibility differs from sildenafil or vardenafil. Daily 2.5 mg and 5 mg tadalafil regimens aim for steady-state exposure; PRN 10 mg and 20 mg regimens rely on long half-life rather than fast peak. Switching generic tadalafil manufacturers should preserve strength and daily versus PRN intent-mixing regimens is a prescribing error, not a generic issue.

Fed BE studies are optional or required depending on the PSG and whether the innovator's labeling emphasizes fed-state dosing. When a fed study is required, meals are standardized-caloric and fat content specified-to reduce variability. A patient who passes BE fasting but always takes sildenafil after steak and wine may experience slower onset than the volunteer who fasted overnight; that is pharmacology, not substandard manufacturing.

Dissolution testing across pH 1.2, 4.5, and 6.8 supports biopharmaceutics consistency but does not replace in vivo BE. Gastric pH, motility, and splanchnic blood flow after meals introduce variability that population-average BE cannot erase.

Practical counseling: for sildenafil and vardenafil, plan dose 60 minutes before activity on an empty or light stomach if onset matters; for tadalafil PRN, food is less critical but alcohol-heavy evenings still impair performance through other mechanisms. Changing meal patterns after a generic switch explains many "it doesn't work like before" calls when the tablet is AB-rated.

Alcohol pharmacokinetics interact separately from BE design. Labels warn about orthostatic hypotension with ethanol; generic status does not remove that advisory. A patient comparing brand memory from a sober hotel weekend to generic use after restaurant dining confounds food, alcohol, and expectation.

Grapefruit juice inhibits intestinal CYP3A4, raising PDE5 exposure through the same mechanism as ketoconazole at lower magnitude. Generic labeling carries identical warnings because the active moiety is unchanged.

Splitting tablets to save cost breaks assumptions of BE studies conducted on intact scored or unscored products. Unless the product is scored and labeled for splitting, discourage pill splitting-it introduces dose inaccuracy unrelated to manufacturer quality.

Internet-Sourced Tablets Versus U.S. Licensed Generics

Card note: not every tablet labeled sildenafil on a website passed an FDA ANDA review. Counterfeit and substandard PDE5 products are a supply-chain problem distinct from legitimate generic substitution.

Licensed U.S. generics arrive through wholesalers with pedigree, NDC traceability, and FDA inspection of manufacturing sites listed in the ANDA. AB-rated products have documented BE to the RLD. When a patient obtains tablets from an online vendor without a U.S. prescription pathway, none of that assurance applies. WHO and national regulators repeatedly report counterfeit ED drugs containing wrong doses, wrong active ingredients, or toxic fillers.

Card note: some patients import personal supplies from countries with reputable agencies (Health Canada, EMA members). Those products may be genuine in their home market but lack U.S. Orange Book entries. Potency and tablet size can differ; blister packaging in non-English languages increases dispensing confusion. Clinicians should recommend filling U.S. prescriptions through state-licensed pharmacies rather than endorsing importation.

Compounded sildenafil or tadalafil from local compounding pharmacies sits outside standard AB substitution rules unless the compounder uses an FDA-approved bulk drug substance and follows state regulations. Potency variability and sterility concerns have triggered FDA warning letters. Compounded products are not therapeutically equivalent to ANDA tablets for purposes of insurance substitution or BE assumptions.

Telehealth platforms that prescribe PDE5 inhibitors without cardiovascular screening recreate the same safety issues regardless of whether they ship brand or generic. Generic status does not relax nitrate, riociguat, or alpha-blocker counseling.

When a patient reports sudden loss of efficacy after switching to an internet source, ask where the bottle came from before escalating dose. Laboratory analyses of seized counterfeits show subtherapeutic active content in a substantial fraction of samples. Returning the patient to an AB-rated pharmacy product is the first corrective step when supply integrity is suspect.

Pharmacists can verify NDC, manufacturer, and lot; patients can use FDA BeSafeRx resources to identify illegitimate sellers. MedWatch reporting helps regulators track suspect products.

Social media markets "generic Cialis" without pharmacy oversight. Chemical analysis of seized shipments frequently finds correct API at wrong dose, wrong API, or contaminants including metronidazole and glibenclamide in international counterfeit surveys. Clinical toxicity follows API and dose, not marketing claims.

Vacation pharmacies in resort towns may stock legitimate local generics; U.S. residents should travel with their prescribed NDC-documented supply when possible to avoid confusion. Returning with unlabeled loose tablets complicates future reconciliation.

Price too good to be true online is a diagnostic clue. Licensed U.S. generics compete aggressively but remain tethered to wholesale chains with verifiable NDCs-not anonymous cryptocurrency checkout pages.

FDA Office of Criminal Investigations and international partners periodically seize counterfeit PDE5 operations; patients reading news headlines should distinguish illicit supply chains from their neighborhood generic refill.

Lactose-intolerant patients may notice GI symptoms with one generic's excipient profile and not another's while both remain AB-rated-switch manufacturer for tolerance, not mechanism.

Patient assistance programs for innovator brands still exist but often lose relevance when generic cash price undercuts copay; financial counseling belongs in access conversations alongside BE education.

Counseling: Nitrates and Interactions That Ignore Brand Names

Generic substitution changes excipients and price-not contraindications. Organic nitrates, nitric oxide donors, and guanylate cyclase stimulators remain absolute contraindications for every AB-rated PDE5 tablet.

Mechanism drives the rule: nitrates raise cGMP through nitric oxide-soluble guanylate cyclase signaling; PDE5 inhibitors block degradation of that cGMP. Combined pathways produce synergistic vasodilation, refractory hypotension, myocardial ischemia, and reported deaths. The interaction is pharmacodynamic class effect. A cheap generic sildenafil kills the same way an innovator tablet does if taken with sublingual nitroglycerin.

Counsel every new fill, not just the first. Medication reconciliation catches isosorbide mononitrate started by cardiology six months after urology prescribed tadalafil. Ask about nitroglycerin for chest pain, isosorbide dinitrate, amyl nitrite recreational use, and riociguat for pulmonary hypertension. Alpha-blockers require dose separation and blood pressure monitoring but are not absolute contraindications when stable.

CYP3A4 inhibitors-ketoconazole, ritonavir, clarithromycin, grapefruit in large quantities-raise sildenafil and vardenafil exposure; labeling caps sildenafil at 25 mg with potent inhibitors. Tadalafil has a longer half-life; interaction windows extend accordingly. Generic manufacturer changes do not alter enzyme inhibition math.

Emergency departments occasionally need nitrates in patients who recently took a PDE5 inhibitor. Labeling emphasizes avoidance; literature discusses extended washout intervals for sildenafil versus tadalafil based on half-life. Document last dose when possible.

Visual disturbances from PDE6 cross-reactivity and rare hearing loss warnings appear in class labeling replicated across ANDA products. Hypotension symptoms-dizziness, syncope-warrant dose reduction and cardiovascular review, not automatic brand upgrade.

Patient teach-back: "If you use nitroglycerin for chest pain, this medication is not safe." That sentence belongs in every generic counseling session regardless of tablet color.

Hospital discharge lists deserve scrutiny. A man admitted for chest pain rule-out may receive sublingual nitroglycerin PRN while outpatient urology continues tadalafil unless someone reconciles the pair. Hold PDE5 therapy until nitrate need is clarified or document explicit non-overlap intervals per specialist agreement.

PDE5 inhibitors modestly lower blood pressure in normotensive men. Combined with antihypertensives the effect is usually tolerable; combined with nitrates it is not. Alpha-blocker co-therapy for BPH requires staggered dosing per labels-tamsulosin stability before PDE5 initiation remains standard advice for all AB products.

Pharmacist override of interaction alerts should not dismiss nitrate pairings as low severity. Hard stops save lives; soft alerts for CYP3A4 pairs need clinician adjudication with dose caps from labeling.

Card note: men with stable angina may carry sublingual nitroglycerin for exertional chest pain while a urologist holds a PDE5 script-those two medications must never overlap in time. Cardiology and urology notes should state the mutual exclusion explicitly so emergency clinicians are not left inferring from fragmented records.

Card note: hospital formularies stock sublingual nitroglycerin on every ward; outpatient PDE5 use is common. Admission medication history must flag the pair even when the patient is not currently chest-pain active-prophylactic nitrates still count.

What an ANDA card actually proves

FDA-approved generic sildenafil, tadalafil, and vardenafil tablets are pharmaceutical equivalents of their reference products with bioequivalence demonstrated under PSG-specified conditions-usually fasting for sildenafil and vardenafil, with tadalafil sharing minimal food-effect labeling but similar ANDA pathways.

Orange Book AB ratings authorize pharmacy substitution within the same molecule and strength. Switching manufacturers among AB products is regulatory sound; switching molecules is a therapeutic decision requiring new dosing education.

Fed versus fasted BE design mirrors innovator food-effect data. Meal timing counseling persists after generic switch for sildenafil and vardenafil. Internet and counterfeit sources bypass BE assurance entirely-distinct from legitimate generic interchange.

Nitrate and riociguat contraindications, CYP3A4 interaction limits, and requirement for sexual stimulation are unchanged by generic status. Suspected therapeutic failure after AB switch warrants adherence and timing review, trial of another AB manufacturer, then dose or molecule adjustment-not assumption that generic is substandard.

Card note: when sourced from licensed U.S. pharmacies, generic PDE5 inhibitors are appropriate default therapy. Your counseling quality matters more than the logo stamped on the tablet.

Perceived efficacy loss after manufacturer change often reflects nocebo when tablet color shifts. Structured re-trial at correct dose and timing on multiple occasions before class switch aligns with urology guideline logic. Document manufacturer name and lot if reporting to FDA for suspected quality defects.

Dissolution failures triggering recall illustrate that GMP compliance continues after BE approval. Patients holding recalled lots should exchange through pharmacy channels rather than abandoning pharmacotherapy altogether when supply is replaceable.

Cross-reference the erectile dysfunction pharmacology topic on this site for mechanism and agent selection; cross-reference sildenafil, tadalafil, and vardenafil monographs for molecule-specific PK and interaction tables when counseling generic fills.

Card note: manufacturers occasionally discontinue specific ANDA products during consolidation; pharmacy switches to another AB-rated supplier is routine. Notify patients that color change alone is not a safety signal when NDC maps to an approved generic.

Keep a one-page patient handout on meals, timing, nitrates, and licensed pharmacy sourcing-reuse it for every PDE5 generic fill to reduce repetitive phone calls.

FDA MedWatch accepts reports of suspected lack of efficacy or adverse events for specific generic lots; clinicians contribute post-marketing signal detection when a pattern emerges across patients switched to one NDC.

Card note: residents rotating through urology and primary care should verbalize the 80-125% CI rule once and the nitrate contraindication twice-those two facts prevent more harm than debating brand loyalty.

Batch-to-batch variability within one manufacturer's GMP system stays tight; switching among AB-rated ANDA holders is not expected to produce clinically detectable PK shifts in the median patient, though individual outliers exist.

If your institution tracks medication errors, include PDE5 strength confusion and nitrate co-prescription as preventable categories in quality review-both exceed generic substitution questions in actual harm potential.